metabolic research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-21. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
On June 28, the Senate voted on a procedural motion to begin debate on the bill. Initially, fiscal conservatives Ron Johnson and Rand Paul, along with moderate Thom Tillis, voted against the motion, while fiscal conservatives Rick Scott, Mike Lee, and Cynthia Lummis, as well as moderate Lisa Murkowski, withheld their votes. After hours of negotiations, which resulted in Alaska specific provisions for Murkowski and Republican leadership support for an amendment vote that would result in increased Medicaid cuts targeted at the fiscal conservatives, Johnson, Scott, Lee, Lummis and Murkowski voted for the motion. The passage of the motion to proceed began the "vote-a-rama" process, in which senators can propose an unlimited number of amendments to the bill. Before it could begin, Democrats required the clerks of the Senate to read the entire 940 page bill in order to highlight Medicaid cuts. The vote-a-rama began two days later, on June 30, in the early morning. One of the few successful amendment votes, passing 99–1, removed the proposed AI law moratorium. The vote-a-rama set a record for the most amendment votes in Senate history. After an over 24-hour vote-a-rama, the bill passed the Senate on July 1, 2025, in a mostly party-line 51–50 vote. All Senate Democrats voted against the bill, and Republicans Rand Paul, Thom Tillis, and Susan Collins of Maine broke from their party to vote against the bill as well. Faced with a tie vote, Republican vice president JD Vance cast a tie-breaking vote in favor of the bill.
=== Trade war === Political scientist Hilmar Mjelde called Trump's actions a "political own goal of historic proportions", and said he believes Trump has underestimated European steadfastness. Annie Genevard said the EU has strong leverage and can retaliate in a trade war with the US, and that it could be "deadly for the United States", emphasising that Europeans will not let the US do as it pleases.
Acetaldehyde (ethereal) Hexanal (green, grassy) cis-3-Hexenal (green tomatoes) Furfural (burnt oats) Hexyl cinnamaldehyde Isovaleraldehyde – nutty, fruity, cocoa-like Anisic aldehyde – floral, sweet, hawthorn. It is a crucial component of chocolate, vanilla, strawberry, raspberry, apricot, and others. Cuminaldehyde – Spicy, cumin-like, green
Sources: en.wikipedia.org
== Personal life == Yates lives in Marbella with his wife, Brazilian fitness model Glauce "Gal" Ferreira, whom he had met at the 2008 Arnold Classic. His son with his ex-wife Deb is also a bodybuilder and the two work closely together. Yates practises yoga every day and has described yoga and meditation as life-altering experiences. He has endorsed the use of psychedelics such as ayahuasca for religious and spiritual purposes. He is open about his cannabis use, which predates his bodybuilding career; in a July 2017 appearance on The Joe Rogan Experience, he stated that cannabis has "anti-cancer" properties and said that he is an advocate for its legalisation for this reason in addition to its relaxing properties and temporary increases in respiratory capacity. Yates revealed his belief in Holocaust denial theories whilst being interviewed by Dave Palumbo in April 2018, claiming that the Holocaust death toll had been "exaggerated" and that two forensic studies (which he did not provide the names of) had concluded that no gas was ever used at the Auschwitz concentration camp.
After finding out that Apoth was using children to disseminate a technological drug called Overclock, Mister Sinister modified Overclock to allow Psylocke to interact with Apoth in a cyberspace, killing Apoth, whose remains she delivered to Mister Sinister in exchange for his assistance in keeping this extrajudicial mission a secret from the Krakoan Quiet Council. Following the Apoth incident, Psylocke was assigned to monitor Mister Sinister's new team of Hellions, composed of mutants considered too violent or troubled to assimilate into Krakoan society. The character was later featured as a team member in the Marauders (vol. 2) as the team was refocused on their mission of mutant rescue. Following the fall of Krakoa, Kwannon headlined Psylocke (vol. 2), written by Alyssa Wong with art by Vincenzo Carratù, spun out of the events of Jed MacKay and Ryan Stegman's X-Men (vol. 7) where Kwannon was a team member.
Bowfin are physostomes, meaning they have a small "pneumatic duct" that connects their swim bladders to their digestive tracts. This allows them, like lungfish, to "breathe" in two ways; they can extract oxygen from the water when breathing through their gills, but can also break the water's surface to breathe or gulp air through the pneumatic duct. When performing low-level physical activity, bowfin obtain more than half of their oxygen from breathing air. The fish have two distinct air-breathing mechanisms used to ventilate the gas bladder. Air-breathing type I is consistent with the action of exhale/inhale exchange, stimulated by either air or water hypoxia, to regulate O2 gas exchange; type II air breaths are inhalation alone, which is believed to regulate gas bladder volume to control buoyancy. Bimodal respiration helps bowfin survive and maintain their metabolic rate in hypoxic conditions. Bowfin breathe air more frequently when they are in darkness, and correspondingly more active. Bowfin blood can adapt to warm, acidic waters. The fish becomes inactive in waters below 10 °C (50 °F); at this temperature, they breathe almost no air, but with increasing temperature, their air breathing increases. Their preferred temperature range is between 12 and 26 °C (54 and 79 °F), with 18 °C (64 °F) the temperature of maximum activity. Air breathing is at a maximum in the range 18.4–29.6 °C (65.1–85.3 °F). Bowfin do not use central chemoreceptor regulation for respiration control.
Sources: en.wikipedia.org
=== G04BD Drugs for urinary frequency and incontinence === G04BD01 Emepronium G04BD02 Flavoxate G04BD03 Meladrazine G04BD04 Oxybutynin G04BD05 Terodiline G04BD06 Propiverine G04BD07 Tolterodine G04BD08 Solifenacin G04BD09 Trospium G04BD10 Darifenacin G04BD11 Fesoterodine G04BD12 Mirabegron G04BD13 Desfesoterodine G04BD14 Imidafenacin G04BD15 Vibegron
== Structure == IDH1 is one of three isocitrate dehydrogenase isozymes, the other two being IDH2 and IDH3, and encoded by one of five isocitrate dehydrogenase genes, which are IDH1, IDH2, IDH3A, IDH3B, and IDH3G. IDH1 forms an asymmetric homodimer in the cytoplasm and carries out its function through two hydrophilic active sites formed by both protein subunits. Each subunit or monomer is composed of three domains: a large domain (residues 1–103 and 286–414), a small domain (residues 104–136 and 186–285), and a clasp domain (residues 137 to 185). The large domain contains a Rossmann fold, while the small domain forms an α/β sandwich structure, and the clasp domain folds as two stacked double-stranded anti-parallel β-sheets. A β-sheet joins the large and small domains and is flanked by two clefts on opposite sides. The deep cleft, also known as the active site, is formed by the large and small domains of one subunit and a small domain of the other subunit. This active site includes the NADP-binding site and the isocitrate-metal ion-binding site. The shallow cleft, also referred to as the back cleft, is formed by both domains of one subunit and participates in the conformational changes of homodimeric IDH1. Finally, the clasp domains of both subunits intertwine to form a double layer of four-stranded anti-parallel β-sheets linking together the two subunits and the two active sites. Furthermore, conformational changes to the subunits and a conserved structure at the active site affect the activity of the enzyme.
During the realignment of several conferences within northeastern Wisconsin, eight schools (Berlin, Campbellsport, Kettle Moraine Lutheran, Kewaskum, Plymouth, Ripon, Waupun and Winneconne) joined together to form a new East Central Conference in 2015. Three of the members of the new ECC were also members of the original conference (Berlin, Ripon and Winneconne). In 2021, after a previous unsuccessful attempt two years prior, Campbellsport left the East Central Conference to join the Wisconsin Flyway Conference, leaving the ECC with seven members. That same year, Berlin and Ripon requested a move to the nearby South Central Conference due to declining enrollment and competitive disparity. Winneconne also requested a shift to the Bay Conference due to its growth and West De Pere's desire to move to the larger Fox River Classic Conference. Both requests were denied by the WIAA Task Force due to a lack of solution to move the other four schools. In December 2023, the other four schools requested an exit from the East Central Conference. Kettle Moraine Lutheran wanted to join other private schools in the Midwest Classic Conference, Kewaskum and Plymouth sought membership in the North Shore Conference and Waupun requested a shift to the Capitol Conference. After some deliberation, the decision was made to disband the East Central Conference and disperse its member schools to other conference.
A&W also sells their Mozza Burger, which is not part of the burger family nor the value menu. It consists of a beef patty, lettuce, tomato, bacon, mozzarella cheese, and their special Mozza sauce on a sesame seed bun. Discontinued offerings include Bone-in Chubby Chicken (sold in 2-3 piece combos, buckets of 10, with a "family box" of fries/onion rings, and a side of potato salad/coleslaw (also discontinued options)), discontinued members of the Burger Family: Grandma Burger, a prime rib burger topped with caramelized onions and horseradish sauce; and the Sirloin Burger Twins, which were a pair of sliders, the Veggie Deluxe (veggie burger with mozzarella cheese, lettuce, tomato, onion, and pickles), traditional hot dogs, and the Whistle Dog (topped with cheese and bacon). The ketchup and mustard served at A&W location are processed by French's at their Ontario facility and use only Canadian ingredients. The Whistle Dog, a hot dog dressed with cheese, bacon and relish, was available in Canada, but was discontinued at the end of 2016; the regular hot dog was similarly discontinued. In July 2022, all Canadian A&W locations brought back the Whistle Dog for a limited time.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.